Chandra Bhagat Pharma Ltd
Chandra Bhagat Pharma Ltd (CBPL) last traded at ₹49.9, a market capitalisation of ₹37.6 crore, on a P/E of 12.3. Over the past 52 weeks the stock has ranged between ₹29.7 and ₹55. Chandra Bhagat Pharma Ltd last reported results for the quarter ended Mar 2026, with sales of ₹91 crore and net profit of ₹3 crore. The next scheduled event is an EGM on 1 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Chandra Bhagat Pharma Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Chandra Bhagat Pharma Ltd quarterly results
In the quarter ended Mar 2026, sales were ₹91 cr, up 313.6% from ₹22 cr a year earlier.
| ₹ crore | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 44 | 75 | 119 | 102 | 65 | 22 | 26 | 91 |
| Expenses | 43 | 74 | 124 | 104 | 66 | 22 | 24 | 89 |
| Operating profit | 1 | 2 | -5 | -2 | -1 | -0 | 2 | 2 |
| OPM % | 2.3% | 2.4% | -4.2% | -2.0% | -1.8% | -1.2% | 7% | 2.4% |
| Other income | 1 | 0 | 7 | 4 | 3 | 2 | 0 | 3 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Profit before tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 |
| Tax % | 31% | 15% | 32% | 34% | -11% | 69% | 22% | 26% |
| Net profit | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 3 |
| EPS (₹) | 0.49 | 0.72 | 0.83 | 1.19 | 0.90 | 0.23 | 0.60 | 3.45 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Chandra Bhagat Pharma Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 71 | 94 | 120 | 221 | 89 | 116 |
| Operating profit | 4 | 3 | 3 | -7 | 1 | 4 |
| OPM % | 5% | 3.0% | 2.8% | -3.2% | 0.7% | 3.3% |
| Net profit | 0 | 1 | 1 | 2 | 1 | 3 |
| EPS (₹) | 0.25 | 1.06 | 1.21 | 2.03 | 1.14 | 4.04 |
TTM is the trailing twelve months to the most recent quarter.
Chandra Bhagat Pharma Ltd growth and returns
- 10 Years
- 4%
- 5 Years
- 10%
- 3 Years
- -1%
- TTM
- 31%
- 10 Years
- 24%
- 5 Years
- 74%
- 3 Years
- 50%
- TTM
- 330%
- 10 Years
- %
- 5 Years
- -12%
- 3 Years
- -29%
- 1 Year
- -10%
- 10 Years
- 5%
- 5 Years
- 5%
- 3 Years
- 6%
- Last Year
- 10%
Chandra Bhagat Pharma Ltd shareholding pattern
Promoters held 73.02% at Mar 2026, up from 68.77% at Mar 2024. FIIs 0.00% and DIIs 0.00%.
| % held | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 69.09% | 68.24% | 68.69% | 68.77% | 69.29% | 71.20% | 72.19% | 73.02% |
| FIIs | 0.85% | 0.85% | 1.33% | 1.33% | 0.48% | 0.61% | 0.61% | 0.00% |
| DIIs | 0.00% | 0.00% | 0.89% | 0.89% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 30.07% | 30.91% | 29.09% | 29.02% | 30.23% | 28.18% | 27.20% | 26.99% |
| No. of shareholders | 126 | 146 | 134 | 152 | 315 | 316 | 301 | 280 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Chandra Bhagat Pharma Ltd events
The next scheduled event is an EGM on 1 Sept 2026.
- EGMApproval for preferential issue of 6.6 million convertible warrants and increase in authorised share capital
- AGM23rd Annual General Meeting, including increase in authorized share capital and preferential issue of convertible warrants
See the full results calendar for every Indian company reporting in the next 30 days.
Chandra Bhagat Pharma Ltd corporate filings
- Corrigendum Of AGM NoticeCompany Updatelow impact
Cruxal's analysis: Chandra Bhagat Pharma Limited has issued a corrigendum to its Annual General Meeting…
Read the full analysis - Notice Of Shareholders Meeting Scheduled On 1St September, 2026AGM/EGMhigh impact
Cruxal's analysis: Chandra Bhagat Pharma Limited has announced a preferential issue of 66,00,000 convertible…
Read the full analysis - Annual Report 2025-26Otherslow impact
Cruxal's analysis: Chandra Bhagat Pharma Ltd has filed its Annual Report for the financial year 2025-26. The…
Read the full analysis - Board Meeting Outcome for For Approval Of Preferential Issue And Other AgendaBoard Meetinghigh impact
Cruxal's analysis: Chandra Bhagat Pharma Limited has approved a significant capital infusion through the…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Chandra Bhagat Pharma Ltd
Cruxal reads every Chandra Bhagat Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.